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Abstract: Follicular lymphoma, the second most common non-Hodgkin lymphoma (NHL), primarily
affects adults and shows an indolent clinical course. Rare cases of follicular lymphoma transform
to a high-grade B-cell lymphoma with MYC and BCL2 rearrangements or “double-hit lymphoma”.
Transformation to a “double-hit lymphoma” portends a worse prognosis and requires aggressive
treatment. We report a comprehensive clinical, pathologic and radiographic review of a patient
with previously undiagnosed low-grade follicular lymphoma that transformed into a “double-hit
lymphoma”. The patient presented with a large heterogeneous mass 16 x 19 cm involving pancreatic
head and neck and a mildly enlarged inguinal lymph node. Positron emission tomography (PET) study
demonstrated Fluorodeoxyglucose (18F) (FDG)-avid peripancreatic mass. Tissue biopsy demonstrated
a high-grade B-cell lymphoma with rearrangements t(14;18) and MYC, leading to the diagnosis of
high-grade B-cell lymphoma with MYC and BCL2 rearrangements. Excisional biopsy of an inguinal
lymph node demonstrated low-grade follicular lymphoma. Clonality studies demonstrated the same
immunoglobulin clone V7-4 in inguinal lymph node and peripancreatic mass. Therefore, diagnosis of
a high-grade B-cell lymphoma with MYC and BCL2 rearrangements that transformed from a low-grade
follicular lymphoma was rendered. It is ultimately important to establish a tissue-based diagnosis at
the different sites that are involved with lymphoma. Patient proceeded with the aggressive treatment
with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab
(EPOCH-R) treatment.
Keywords: double-hit lymphoma 1; follicular lymphoma 2; CT scan 3
1. Introduction
Follicular lymphoma is the second most common non-Hodgkin lymphoma and it accounts for
approximately 20% of all non-Hodgkin lymphoma [1]. The estimated incidence of follicular lymphoma
in the United States is 3.18 cases per 100,000 people and it constitutes 35% of all non-Hodgkin
lymphoma [2]. Incidence of follicular lymphoma in Europe 2.18 per 100,000 people [3]. Although
follicular lymphoma affects all races, its incidence in Whites is double of that in Asians and Blacks.
Incidence of follicular lymphoma rises with age and the median age of diagnosis is 65 years [1].
Patients usually present with painless peripheral and central lymphadenopathy. Staging studies
usually demonstrate splenomegaly, liver and bone marrow involvement in 40, 50 and up to 80 percent
of cases, respectively [4]. Despite the widespread disease, B-symptoms, such as fever and weight loss,
are uncommon. Radiographically, CT and MRI are useful tools in assessing the extent of the disease.
FDG-PET studies are instrumental in identifying patients with high risk of transformation [5].
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Histological sections of the lymph nodes involved by follicular lymphoma show a follicular
growth pattern, with tightly arranged neoplastic follicles that efface normal lymph node architecture [6].
Neoplastic follicles are composed of randomly admixed centrocytes and centroblasts and lack tingible
body macrophages. Enumeration of centroblasts is used to determine the tumor grade, which has
therapeutic implications. It is imperative to distinguish high-grade (grade 3A and 3B) from low-grade
(grade 1 and 2), since therapy is guided by the grade of follicular lymphoma. Grade 1 and 2 follicular
lymphoma contain 0–5 and 5–15 centroblasts per high-power field, respectively. Grade 3 lesions
contain more than 15 centroblasts, but centrocytes are present in Grade 3A and absent in Grade 3B.
Grade 3 follicular lymphoma is usually managed similarly to high-grade B-cell lymphoma. Follicular
lymphoma cells are neoplastic B-cells that have a germinal center origin, and express B-cell markers
(CD19, CD20, CD79a) and germinal center markers (Bcl6 and CD10). Ninety percent of grade
1–2 follicular lymphomas harbor a t(14;18)(q32;q21) translocation that results in the fusion of the
anti-apoptotic gene BCL2 on chromosome 18 to heavy-chain IGH on chromosome 14 (BCL2/IGH) [7].
Therefore, the majority of low-grade follicular lymphoma cells overexpress Bcl2, which is not expressed
in reactive germinal centers. Overexpression of anti-apoptotic Bcl2 protein results in the persistence of
the neoplastic clone.
Histologic transformation or transformation of follicular lymphoma to a clinically aggressive
subtype of lymphoma (commonly diffuse large B-cell lymphoma) occurs at approximately 2–3 percent
per year [8]. A recent large prospective National Lympho Care Study (NLCS) of 2700 patients reported
the 5- and 8-year transformation rates to be 13 and 19 percent, respectively [9]. At the time of
transformation, approximately 25% of cases meet the criteria for high-grade B cell lymphoma with
MYC and BCL-2 and/or BCL-6 rearrangements (“double-hit” lymphoma) [7]. Follicular lymphoma
that transforms to a “double-hit lymphoma” is characterized by the MYC aberrations, including
rearrangements and amplifications [10]. Progression to a high-grade B-cell lymphoma is associated
with increased lymphadenopathy, the infiltration of extranodal sites, and the development of systemic
symptoms [11]. The gold standard to diagnose transformation requires a biopsy from the involved
lymph nodes or extranodal tissue that demonstrates sheets of large tumor cells and loss of the follicular
architecture. These tumors resemble diffuse large B-cell lymphoma (DLBCL) or other aggressive
lymphomas, and have high proliferative index, as indicated by Ki-67 immunostaining. Transformation
to “double-hit lymphoma” warrants more aggressive treatment in comparison to transformation of
DLBCL [11]. Therefore, it is imperative to perform Fluorescent in situ Hybridization (FISH) studies to
determine rearrangements of MYC, in addition to t(14;18) or BCL2/IGH.
We report a comprehensive clinical, pathologic including molecular clonality studies and a
radiologic review of a case of low-grade follicular lymphoma that progressed to a so-called “double-hit
lymphoma” with BCL2/IGH and MYC rearrangements. Double-hit lymphoma was identified in
the peripancreatic mass and demonstrated t(14;18) or BCL2/IGH, and rearrangement of MYC 8q32.
Low-grade follicular lymphoma was diagnosed based on the excisional biopsy of an inguinal lymph
node. In addition, molecular clonality studies confirmed the same origin of the low-grade and
high-grade components of lymphoma. The next-generation sequencing of the immunoglobulin
variable region determined the same clone, V7-4, in low-grade follicular lymphoma involving the
inguinal lymph node and high-grade lymphoma with BCL2/IGH and MYC rearrangements involving
the peripancreatic region. In order to establish accurate diagnosis, it is important to biopsy different
sites that are involved with the lymphoma.
2. Case Presentation
A 57-year-old Asian female, with a past medical history of hypertension, hypercholesterolemia
and pre-diabetes, presented with abdominal distension and acute right upper quadrant pain. She was
in her usual state of good health until two month ago, when she developed B symptoms to include
fatigue, fever, night sweats, chills and abdominal distension. Her symptoms progressed and included
8-pound weight loss, abdominal distension and pain that required evaluation through the Emergency
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Department. On physical examination, patient appeared visibly jaundiced, with a palpable centrally
located abdominal mass. Labs showed mild moderate hypochromic anemia and mild leukocytosis. CT,
with contrast of the abdomen and pelvis, revealed a large lobulated and heterogeneously enhancing
mass, measuring 16 × 19 cm, involving the pancreatic head and uncinate region. There was also bulky
lymphadenopathy encasing the superior mesenteric vessels (Figure 1 A–C). A PET scan showed FDG
avid peripancreatic mass and superior mesenteric lymphadenopathy (Figure 1D) This case falls under
category 4 of 45 CFR 46.101(b) Categories of Exempt Human Subjects Research. Research involving
the collection or study of existing data, documents, records, pathological specimens or diagnostic
specimens, if these sources are publicly available or the information is recorded by the investigator
in such a manner that the subjects cannot be identified directly or through identifiers linked to the
subjects. Furthermore, we do not require a signed authorization for case reports when there is not
attached identifiable information: A HIPAA Authorization from the subject(s) of the Case Report is not
required if there is access to PHI however there is no disclosure of PHI (outside of the covered/hybrid
entity) in the Case Report publication.
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Figure 1. Initial abdominal and pelvic CT with contrast, prior to treatment. (A). sagittal, (B). coronal,
and (C). transverse planes show a large lobulated heterogeneous mass involving the head of the
pancreas and retroperitoneum. It measures approximately 19 x 22 cm (craniocaudal x transverse).
(D). PET-FDG study demonstrates peripancreatic heterogeneous FDG-avid mesenteric mass (SUV 6.0).
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In addition, a mildly enlarged 1.2 cm right inguinal lymph node was identified. The patient
proceeded with an endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of the peripancreatic
mass and ERCP with stent placement. The histopathologic evaluation revealed sheets of large atypical
lymphocytes with hyperchromatic nuclei, irregular nuclear contours and scant cytoplasm (Figure 2A).
Diagnostics 2019, 9, x FOR PEER REVIEW 4 of 9 
 
pancreas and retroperitoneum. It measures approximately 19 x 22 cm (craniocaudal x transverse). (D). 
PET-FDG study demonstrates peripancreatic heterogeneous FDG-avid mesenteric mass (SUV 6.0). 
In addition, a mildly enlarged 1.2 cm right inguinal lymph node was identified. The patient 
proceeded with an endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of the 
peripancreatic mass and ERCP with stent placement. The histopathologic evaluation revealed sheets 
of large atypical lymphocytes with hyperchromatic nuclei, irregular nuclear contours and scant 
cytoplasm (Figure 2A).  
 
Figure 2. Endoscopic ultrasound-guided fine needle aspiration of the peripancreatic mass 
demonstrates sheets of large lymphocytes (A), that express B-cell marker CD20 (B), follicular center 
CD10 (C), anti-apoptotic protein Bcl2 (D), c-myc oncoprotein (E) and high levels of Ki-67 proliferative 
marker (F). Overall, histomorphologically and immunophenotypically consistent with diffuse large 
B-cell lymphoma. 
Architectural pattern could not be appreciated due to the limitations of the FNA biopsy. 
Immunophenotypic studies revealed that atypical lymphocytes are neoplastic B-cells that express 
surface kappa light chain (by flow cytometry), CD20, CD10, Bcl-2, Bcl-6 and c-myc (Figure 2B–E). 
Neoplastic B-cells were negative for MUM-1, TdT and CD3. Epstein-Barr virus (EBV) was negative 
by EBV-encoded small RNA (EBER) in situ hybridization. Proliferative index, as judged by Ki-67 
immunostain, was increased and estimated to be positive in 85% of cells (Figure 2F). Corresponding 
Figure 2. Endoscopic ultrasound-guided fine needle aspiration of the peripancreatic mass demonstrates
sheets of large lymphocy es (A), that xpress B-c ll m rke CD20 (B), follicular enter CD10
(C), a ti- poptotic protein Bcl2 (D), c-myc oncoprotein (E) and high levels of Ki-67 proliferative
marker (F). Overall, histomorphologically and immun phenotypically consistent with diffus larg
B-cell lymphoma.
Architectural pattern could not be appreciated due to the limitations of the FNA biopsy.
Immunophenotypic studies revealed that atypical lymphocytes are neoplastic B-cells that express
surface kappa light chain (by flow cytometry), CD20, CD10, Bcl-2, Bcl-6 and c-myc (Figure 2B–E).
Neoplastic B-cells were negative for MUM-1, TdT and 3. Epstein-Barr virus (EBV) was negative
by EBV-encoded small RNA (EBER) in situ hybridization. Proliferative index, as judged by Ki-67
immunostain, was increased and estimated to be positive in 85% of cells (Figure 2F). Corresponding
flow cytometry revealed sixty percent of kappa-restricted lymphoma cells. In this setting, differential
diagnosis with reactive B-cell proliferation is not feasible due to the presence of sheets of highly
atypical B-cells that showed surface kappa-light chain restriction, and an abnormal immunophenotype
profile. Reactive B-cells express CD20, are expected to be smaller, and are usually admixed with T-cells.
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Germinal cell type non-neoplastic B-cells, in addition to CD20, express CD10 and Bcl6, but do not
express Bcl2 and c-myc. Finally, a high proliferative index, estimated by Ki-67 at 85% is indicative of
a high-grade B-cell neoplasm. Overall, histomorphological and immunophenotypic findings were
of DLBCL, germinal center type. Fluorescence in situ hybridization (FISH) analysis was performed
using probes specific to rearrangements involving BCL6, MYC and t(14;18), which are reported in
high-grade/large B-cell lymphomas. The interphase study on the formalin-fixed paraffin-embedded
tissue revealed a break apart signal for MYC (86% of cells, normal <11.6%) and dual fusion signal in the
14;18 (IGH/BCL2) probe set (90% of cells, normal <5.8%). The high-risk “double-hit” lymphomas are
characterized by MYC translocation combined with BCL2 and/or BCL6 translocation. In the appropriate
histomorphological setting, WHO 2016 recommends rendering diagnosis of a High-grade B-cell
lymphoma with MYC and BCL2 rearrangements, also known as “double-hit lymphoma”. Double-hit
lymphomas are aggressive and require a more aggressive treatment than diffuse large B-cell lymphoma,
including an aggressive treatment with chemotherapy and immunotherapy [12].
Translocation 14;18 (IGH/BCL2), although not specific to follicular lymphoma, raised the possibility
of underlying follicular lymphoma that progressed to a high-grade B-cell lymphoma. Underlying
follicular lymphoma can be unequivocally assessed using core needle or an excisional biopsy of the
lymph node. Therefore, an excisional biopsy of the inguinal lymph node was performed. Gross
examination revealed that the lymph node had a vaguely nodular tan-white cut surface. Histological
sections revealed a follicular growth pattern characterized by tightly arranged follicles with attenuated
mantle zones that effaced lymph node architecture (Figure 3A–B). Neoplastic germinal centers showed
predominantly centrocytes with admixed centroblasts, loss of polarity and decreased tingible body
macrophages. The neoplastic follicle center B-cells expressed surface kappa light chain, CD20, CD10,
Bcl-2 and Bcl6 (not shown) (Figure 3 C–F). The follicular growth pattern was also highlighted by the CD21
immunostain that highlighted follicular dendritic cells (Figure 3G). The proliferative index was low, as
judged by Ki-67 immunostaining (Figure 3H). Overall findings are of low-grade follicular lymphoma,
of a predominantly follicular growth pattern, without evidence of transformation to high-grade B-cell
lymphoma. Fluorescence in situ hybridization (FISH) analysis, using probes specific for rearrangements
involving BCL6, MYC and t(14;18), revealed a dual fusion signal in the 14;18 (IGH/BCL2) probe (26% of
cells, normal <5.8%) indicative of IGH/BCL2 fusion. Overall, histomorphological, immunophenotypic
and cytogenetic studies consistent with low-grade follicular lymphoma, grade 1–2 (Figure 3).
In addition, clonality studies using next-generation sequencing of the variable region of the
immunoglobulin gene identified an identical clone, V7-4, in low-grade follicular lymphoma and
high-grade B-cell lymphoma with BCL2 and MYC rearrangements. Therefore, diagnosis of a high-grade
B-cell lymphoma with MYC and BCL2 rearrangements that transformed from a low-grade follicular
lymphoma was rendered. The patient proceeded with the recommended dose-adjusted etoposide,
prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) treatment.
CT of abdomen and pelvis with contrast post cycle 1 DA-EPOCH demonstrated tumor necrosis and a
decrease in the size of peripancreatic mass to 17 × 19 cm (Figure 4).
The patient proceeded to receive cycle 1 of DA-EPOCH-R for induction, cycle 2, 3 and 4
DA-EPOCH-R. Bone marrow and cerebrospinal fluid were not involved with lymphoma. Overall,
patient responded well to therapy. Her post-induction course was complicated by culture-negative
neutropenic fever and headaches.
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Figure 3. Excisional biopsy of the inguinal Endoscopic ultrasound-guided fine-needle aspiration of the
peripancreatic mass demonstrates sheets of large lymphocytes (A), that express B-cell marker CD20 (B),
follicle ce ter CD10 (C), anti-apoptotic protein Bcl2 (D), c-myc oncoprotein (E) and high levels of Ki-67
proliferative marker (F). Overall, histomor h logically and immunophenotypically consistent with
diffuse large B-cell lymphoma.
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the initiation of treatment.
3. Discussion
Follicular lymphoma is one of the most common non-Hodgkin lymphomas that affects all races
worldwide. Interestingly, incidence in Whites is twice than in Asians and Blacks [1,13]. As of
today, risk factors for developing follicular lymphoma, appear to be elusive, with some evidence to
suggest infectious etiology, drugs, toxins and genetic predisposition [4]. The vast majority of follicular
lymphomas have the t(14;18), which results in the overexpression of B cell leukemia/lymphoma
2 (BCL2), an oncogene that blocks programmed cell death (apoptosis), leading to prolonged cell
survival [14]. Over the course of the disease, approximately twenty percent of patients undergo
progression to high-grade B-cell lymphoma [9,15]. The estimated annual rate of disease transformation
is approximately 2–3 percent [2].
It is hypothesized that, initially, follicular lymphoma is comprised of multiple clones that have an
indolent behavior. Transformation occurs through the clonal evolution where the most aggressive
clone undergoes expansion [5,16]. Most commonly, follicular lymphoma transforms into a DLBCL [17].
The initial pathologic evaluation of DLBCL includes a stratification based on the immunohistochemical
profile into germinal center B-cell subtypeand and non-germinal center B–cell subtype lymphomas.
This classification is necessary to predict prognosis, outcomes and guide treatment. Approximately
twenty-five percent of transformed follicular lymphoma acquire MYC rearrangement and transform to
high-grade B cell lymphoma with MYC and BCL2 rearrangements [10]. Transformation to a “double-hit”
lymphoma has been well documented and can present a diagnostic challenge [18–20]. Patients that
transform to “double-hit” lymphoma usually require dose-adjusted etoposide, prednisone, vincristine,
cyclophosphamide, doxorubicin and rituximab (EPOCH-R) [13–15]. An aggressive EPOCH-R regimen
can be potentially curative in the instances of de novo “double-hit” lymphomas. However, it is not
effective in eradicating an underlying low-grade follicular lymphoma. While the major cause of relapse
is due to the high-grade component, in patients with the transformed follicular lymphoma, follicular
lymphoma recurrence can occur [21]. In addition, patients with underlying low-grade lymphoma are
more likely to be resistant to Rituximab and radioimmunotherapy, due to the possible prior treatment
of the low-grade component [21,22].
It is imperative to suspect a high-grade lymphoma in a patient who presents with B-symptoms and
a large abdominal mass. Obtaining tissue from the most aggressive-appearing site is crucial to establish
a diagnosis of a high-grade lymphoma. Comparison of tissue from the other site might be instrumental
in identifying a low-grade component of the lymphoma. FISH studies targeting rearrangements of
Diagnostics 2020, 10, 157 8 of 9
MYC, BCL2 and BCL6 are required to diagnose a double-hit lymphoma. Molecular clonality studies
might be instrumental to establish the same origin in cases of high-grade B-cell lymphoma that do not
show a concurrent low-grade component.
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